Immunome Inc (IMNM NASDAQ) stock market data APIs
$23.356
0.05(0.2%)
as of May 6, 2026
Try our APIs with
free plan!
Immunome Inc Financial Data Overview
Price chart is built with
Anychart
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Prev. Close
23.356
Open
23.406
High
23.4885
Low
23.0146
52 wk Range
7.39-27.65
Market Cap
2 635 M
Shares Outstanding
113 M
Revenue
6 941 K
EPS
0
Beta
2.115
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunome Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunome Inc data using free add-ons & libraries
Get Immunome Inc Fundamental Data
Immunome Inc Fundamental data includes:
- Net Revenue: 6 941 K
- EBITDA: -211 647 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -0.591
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunome Inc News
New
Techne (TECH) Misses Q3 Earnings and Revenue Estimates
Techne (TECH) came out with quarterly earnings of $0.53 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.56 per share a year ago. These figures are a...
Exelixis (EXEL) Tops Q1 Earnings Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.62 per share a year ago. These figures are...
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.58 per share a year ago. These fig...
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
Jack Higgins, Chief Scientific Officer of Immunome(NASDAQ:IMNM), reported the sale of 9,438 shares of common stock in an open-market transaction on April 2, 2026, as disclosed in the SEC Form 4 filing...
Get Immunome Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
